{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Company Reports", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Addyi (Drug)", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Philidor Rx Services LLC", "name": "organizations", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/30/business/valeant-pharmaceuticals-files-overdue-us-2015-financial-report.html", "document_type": "article", "byline": {"person": [], "original": "By THE ASSOCIATED PRESS", "organization": "THE ASSOCIATED PRESS"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "446", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The Canadian drug maker is dealing with three federal inquiries into its accounting and business practices, and a huge plunge in its stock price.", "pub_date": "2016-04-30T04:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Valeant Files U.S. Report as Accounting Issues Linger", "main": "Valeant Pharmaceuticals Files Overdue U.S. 2015 Financial Report"}, "print_page": "6", "snippet": "The Canadian drug maker is dealing with three federal inquiries into its accounting and business practices, and a huge plunge in its stock price.", "_id": "5723f8f938f0d83e7bbb56c8", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals resolves default on some of its $30 billion debt by filing its long-delayed United States financial report for 2015; accounting problems at company linger."}